Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Gyre Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:L9S's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Gyre Therapeutics's adjusted book value per share data for the three months ended in Jun. 2026 was €1.175. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €80.17 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Gyre Therapeutics (FRA:L9S) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Gyre Therapeutics Cyclically Adjusted PB Ratio Related Terms
Gyre Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics Cyclically Adjusted PB Ratio Chart
FRA:L9S vs CTMX, BBOT, TECX: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Gyre Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Cyclically Adjusted PB Ratio falls into.
Gyre Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Gyre Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.08 mean?
Gyre Therapeutics (FRA:L9S) has a Cyclically Adjusted PB Ratio of 0.08 as of Sep. 22, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Gyre Therapeutics and its competitors. According to the industry distribution chart, Gyre Therapeutics ranks #999999 out of 679 companies in the Biotechnology industry.
Is Gyre Therapeutics' Cyclically Adjusted PB Ratio too high?
Gyre Therapeutics' current Cyclically Adjusted PB Ratio is 0.08. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.57. Gyre Therapeutics' value of 0.08 is 94.9% below this industry median. Based on the distribution chart, Gyre Therapeutics ranks #999999 out of 679 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Cyclically Adjusted PB Ratio compare to CTMX and BBOT?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #999999 out of 679 companies for Cyclically Adjusted PB Ratio. This places Gyre Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.57. Gyre Therapeutics' value of 0.08 is 94.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.57, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Cyclically Adjusted PB Ratio of 0.08 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Cyclically Adjusted PB Ratio is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Gyre Therapeutics (FRA:L9S) has a current Cyclically Adjusted PB Ratio of 0.08. The stock's GF Value™ is €8.10, compared to a current price of €6.55 — trading 19.1% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.08 and 94.9% below the Biotechnology industry median of 1.57. Gyre Therapeutics' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Gyre Therapeutics (FRA:L9S), the current Cyclically Adjusted PB Ratio is 0.08 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (FRA:L9S) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of €6.55 is trading 19.1% below its estimated GF Value™ of €8.10.
Key valuation signals for FRA:L9S:
Cyclically Adjusted PB Ratio: 0.08
GF Value™: €8.10 vs. price of €6.55 (19.1% below fair value)
Industry Position: 94.9% below the Biotechnology median (#999999 of 679)
No single metric tells the full story. See the FRA:L9S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score
Get the complete analysis for FRA:L9S
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L9S has been successfully added to your 
